These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 31957270

  • 1. PARP inhibitor Olaparib increases the sensitization to radiotherapy in FaDu cells.
    Liu C, Gross N, Li Y, Li G, Wang Z, Zhong S, Li Y, Hu G.
    J Cell Mol Med; 2020 Feb; 24(4):2444-2450. PubMed ID: 31957270
    [Abstract] [Full Text] [Related]

  • 2. Poly(ADP-ribose)polymerase (PARP) inhibition and anticancer activity of simmiparib, a new inhibitor undergoing clinical trials.
    Yuan B, Ye N, Song SS, Wang YT, Song Z, Chen HD, Chen CH, Huan XJ, Wang YQ, Su Y, Shen YY, Sun YM, Yang XY, Chen Y, Guo SY, Gan Y, Gao ZW, Chen XY, Ding J, He JX, Zhang A, Miao ZH.
    Cancer Lett; 2017 Feb 01; 386():47-56. PubMed ID: 27847302
    [Abstract] [Full Text] [Related]

  • 3. Radiosensitization with an inhibitor of poly(ADP-ribose) glycohydrolase: A comparison with the PARP1/2/3 inhibitor olaparib.
    Gravells P, Neale J, Grant E, Nathubhai A, Smith KM, James DI, Bryant HE.
    DNA Repair (Amst); 2018 Jan 01; 61():25-36. PubMed ID: 29179156
    [Abstract] [Full Text] [Related]

  • 4. Combined inhibition of Wee1 and PARP1/2 for radiosensitization in pancreatic cancer.
    Karnak D, Engelke CG, Parsels LA, Kausar T, Wei D, Robertson JR, Marsh KB, Davis MA, Zhao L, Maybaum J, Lawrence TS, Morgan MA.
    Clin Cancer Res; 2014 Oct 01; 20(19):5085-96. PubMed ID: 25117293
    [Abstract] [Full Text] [Related]

  • 5. Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials.
    Wang L, Yang C, Xie C, Jiang J, Gao M, Fu L, Li Y, Bao X, Fu H, Lou L.
    Cancer Sci; 2019 Mar 01; 110(3):1064-1075. PubMed ID: 30663191
    [Abstract] [Full Text] [Related]

  • 6. Radiosensitization by the PARP inhibitor olaparib in BRCA1-proficient and deficient high-grade serous ovarian carcinomas.
    Bi Y, Verginadis II, Dey S, Lin L, Guo L, Zheng Y, Koumenis C.
    Gynecol Oncol; 2018 Sep 01; 150(3):534-544. PubMed ID: 30025822
    [Abstract] [Full Text] [Related]

  • 7. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A, Im SA, Kim DK, Song SH, Kim HJ, Lee KH, Kim TY, Han SW, Oh DY, Kim TY, O'Connor MJ, Bang YJ.
    Breast Cancer Res; 2015 Mar 07; 17():33. PubMed ID: 25888415
    [Abstract] [Full Text] [Related]

  • 8. PARP inhibitors affect growth, survival and radiation susceptibility of human alveolar and embryonal rhabdomyosarcoma cell lines.
    Camero S, Ceccarelli S, De Felice F, Marampon F, Mannarino O, Camicia L, Vescarelli E, Pontecorvi P, Pizer B, Shukla R, Schiavetti A, Mollace MG, Pizzuti A, Tombolini V, Marchese C, Megiorni F, Dominici C.
    J Cancer Res Clin Oncol; 2019 Jan 07; 145(1):137-152. PubMed ID: 30357520
    [Abstract] [Full Text] [Related]

  • 9. PARP inhibitor olaparib sensitizes cholangiocarcinoma cells to radiation.
    Mao Y, Huang X, Shuang Z, Lin G, Wang J, Duan F, Chen J, Li S.
    Cancer Med; 2018 Apr 07; 7(4):1285-1296. PubMed ID: 29479816
    [Abstract] [Full Text] [Related]

  • 10. [Effect and Mechanism of Radiosensitization of Poly (ADP-Ribose) Polymerase Inhibitor n Lewis Cells and Xenografts].
    Wang W, Duan B, Zeng L.
    Zhongguo Fei Ai Za Zhi; 2016 Jan 07; 19(1):16-23. PubMed ID: 26805733
    [Abstract] [Full Text] [Related]

  • 11. Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint.
    Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J, Shen L.
    J Exp Clin Cancer Res; 2018 Jun 28; 37(1):129. PubMed ID: 29954437
    [Abstract] [Full Text] [Related]

  • 12. Co-targeting poly(ADP-ribose) polymerase (PARP) and histone deacetylase (HDAC) in triple-negative breast cancer: Higher synergism in BRCA mutated cells.
    Marijon H, Lee DH, Ding L, Sun H, Gery S, de Gramont A, Koeffler HP.
    Biomed Pharmacother; 2018 Mar 28; 99():543-551. PubMed ID: 29902865
    [Abstract] [Full Text] [Related]

  • 13. DNA-PK inhibitor AZD7648 is a more portent radiosensitizer than PARP inhibitor Olaparib in BRCA1/2 deficient tumors.
    Wang T, Kyle AH, Baker JHE, Liu NA, Banáth JP, Teymori S, Minchinton AI.
    DNA Repair (Amst); 2024 Jul 28; 139():103689. PubMed ID: 38749239
    [Abstract] [Full Text] [Related]

  • 14. Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo.
    van Erp AEM, van Houdt L, Hillebrandt-Roeffen MHS, van Bree NFHN, Flucke UE, Mentzel T, Shipley J, Desar IME, Fleuren EDG, Versleijen-Jonkers YMH, van der Graaf WTA.
    J Cancer Res Clin Oncol; 2020 Jul 28; 146(7):1659-1670. PubMed ID: 32279088
    [Abstract] [Full Text] [Related]

  • 15. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models.
    Santiago-O'Farrill JM, Weroha SJ, Hou X, Oberg AL, Heinzen EP, Maurer MJ, Pang L, Rask P, Amaravadi RK, Becker SE, Romero I, Rubio MJ, Matias-Guiu X, Santacana M, Llombart-Cussac A, Poveda A, Lu Z, Bast RC.
    Cancer; 2020 Feb 15; 126(4):894-907. PubMed ID: 31714594
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft.
    Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, Wedge SR, Stratford IJ.
    Mol Cancer Ther; 2011 Oct 15; 10(10):1949-58. PubMed ID: 21825006
    [Abstract] [Full Text] [Related]

  • 17. Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
    Du Y, Yamaguchi H, Wei Y, Hsu JL, Wang HL, Hsu YH, Lin WC, Yu WH, Leonard PG, Lee GR, Chen MK, Nakai K, Hsu MC, Chen CT, Sun Y, Wu Y, Chang WC, Huang WC, Liu CL, Chang YC, Chen CH, Park M, Jones P, Hortobagyi GN, Hung MC.
    Nat Med; 2016 Feb 15; 22(2):194-201. PubMed ID: 26779812
    [Abstract] [Full Text] [Related]

  • 18. Combined EGFR1 and PARP1 Inhibition Enhances the Effect of Radiation in Head and Neck Squamous Cell Carcinoma Models.
    Frederick BA, Gupta R, Atilano-Roque A, Su TT, Raben D.
    Radiat Res; 2020 Nov 10; 194(5):519-531. PubMed ID: 32936912
    [Abstract] [Full Text] [Related]

  • 19. Poly-ADP-Ribose Polymerase as a Therapeutic Target in Pediatric Diffuse Intrinsic Pontine Glioma and Pediatric High-Grade Astrocytoma.
    Chornenkyy Y, Agnihotri S, Yu M, Buczkowicz P, Rakopoulos P, Golbourn B, Garzia L, Siddaway R, Leung S, Rutka JT, Taylor MD, Dirks PB, Hawkins C.
    Mol Cancer Ther; 2015 Nov 10; 14(11):2560-8. PubMed ID: 26351319
    [Abstract] [Full Text] [Related]

  • 20. PARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.
    Czyż M, Toma M, Gajos-Michniewicz A, Majchrzak K, Hoser G, Szemraj J, Nieborowska-Skorska M, Cheng P, Gritsyuk D, Levesque M, Dummer R, Sliwinski T, Skorski T.
    Oncotarget; 2016 Nov 15; 7(46):75551-75560. PubMed ID: 27705909
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.